Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Aug 07, 2021 1:35pm
106 Views
Post# 33668494

RE:RE:Cost of Lutathera in Canada

RE:RE:Cost of Lutathera in CanadaIt's too early for them to talk about that. They need efficacy data first. But if TH1902 shows good efficacy, then it will be the time to push that forward.


Wino115 wrote:

This is a key point for their potential profitability. While PL and Marsolais always state the characteristics around TH1902 may be a new paradigm for the way you treat cancer, PL and Dubuc need to start highlighting that this also, by definition, means it could lead to a new financial model paradigm as a result. The characteristic of possibly longer patient treatment periods and more frequent dosing supports a far more robust commercial model versus standard cancer company treatments.  This point needs to be incorporated into their presentation if this supposition is true, which it seems preclinical would support.  

 

 

jfm1330 wrote: I found a pricing reference for Lutathera in Canada. It also includes the pricing for Sandostatin LAR, a peptide drug, and also the cost of chemotherapy drugs for neuroendocrine cancers. The cost of Lutathera is 140,000$ CAN for four cycles, so 35,000$ per dose. Initiation of treatment is four cycles every two months, maybe more if they see good tumor regression. If it's only stable disease, they will treat again when they will see cancer progression again.

The cost of Sandostatin LAR (Octreotide LAR 60 mg) is 4000$ CAN per dose, with a dose every four weeks, so 52,000$ per year only for a long acting release formulation of the peptide. So it gives a good idea of the pricing TH1902 and other PDCs derived from TH19P01 could achieve. I did not find the pricing in the US, but it is surely higher by a good margin.

So imagine the pricing for a PDC like TH1902 with treatment cycles of three weeks, instead of two months. You could end up maybe with 10 to 20 cycles of treatment given the expected wider therapeutic window. Obviously, it needs to be efficaciuous.

https://www.cadth.ca/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_inEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf

 

 

 



<< Previous
Bullboard Posts
Next >>